Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Jonathan Wade GoldmanSarina A Piha-PaulBrendan D CurtiKatrina S PedersenTodd M BauerStefanie L GroenlandRichard D CarvajalVaishali ChhayaGray KirbyKelly McGlincheyScott A HammondKatie StreicherDanielle M TownsleyYoung Kwang ChaeJens VoortmanAurélien MarabelleJohn D PowderlyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Following dose escalation, moderate toxicity was observed in both treatment arms, with no clear efficacy signals demonstrated.